

Fitch upgrades Hikma Pharmaceuticals PLC's long-term issuer default rating to 'BBB', outlook stable

London, 29 May 2025 - Hikma Pharmaceuticals PLC (Hikma, Company) is pleased to announce that Fitch has upgraded its long-term issuer default rating and the senior unsecured rating on Hikma Finance USA LLC's 500 million notes to 'BBB' from 'BBB-' with a stable outlook.

Khalid Nablisi, CFO of Hikma said: "I am pleased that now both Fitch and S&P have upgraded Hikma to BBB, reinforcing our investment grade rating. These upgrades are a strong endorsement of our strategic direction, financial discipline, and operational resilience. They underscore Hikma's solid market position across key geographies and reflect confidence in our ability to consistently deliver strong financial results, supported by our diversified business model, robust balance sheet, and prudent capital allocation."

– ENDS –

Enquiries:

Hikma (Investors)

Susan Ringdal EVP, Strategic Planning and Global Affairs	+44 (0)20 7399 2760/ +44 (0)7776 477050
Guy Featherstone Director, Investor Relations	+44 (0)20 3892 4389/ +44 (0)7795 896738
Layan Kalisse Senior Associate, Investor Relations	+44 (0)20 7399 2788/ +44 (0)7970 709912

FTI Consulting (Media)

Ciara Martin	+44 (0)7779 775979
--------------	--------------------

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

©2025 Hikma Pharmaceuticals PLC. All rights reserved.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEASSNASXSEEA